Navigation Links
Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
Date:3/27/2012

ional Institute of Allergy and Infectious Disease (NIAID) grant supporting development of new vaccine technology known as ThermoVax™. Soligenix is also developing SGX202 for the treatment of gastrointestinal acute radiation syndrome (GI ARS) and has demonstrated statistically significant preclinical survival results in a canine GI ARS model.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other r
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
2. Soligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
3. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
4. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
5. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
6. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
7. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
10. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
11. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... As part of its philanthropic partnership with ... Foundation funded a $3.25 million project to relocate and ... most up-to-date features and technology. , The new pharmacy ... staff members will begin moving from the current location ... days. , The current pharmacy has been using ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... The global genotyping market is expected to grow ... of 2015 to 2020 to reach $17.0billion in 2020. ... and development process and to provide personalized therapy, factors ... investments by key manufacturers to offer advanced and innovative ... Browse 113 market data tables & 37 figures spread ...
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... WILL FOCUS ON COLLECTION, PROCESSING AND STORAGE OF EQUINE ... BONE MARROW AND PLACENTAL TISSUE STEM CELLS, RANCHO ... ), a leading supplier of innovative products and,services that ... its,wholly-owned subsidiary, Vantus, Inc., has signed a formal agreement ...
... Feb. 27 Ocera Therapeutics, a,biopharmaceutical company focused ... to treat a broad range of,gastrointestinal and liver ... joined the company as Chief Medical Officer. Prior ... Chief Medical Officer and Vice,President of Clinical Affairs ...
... Ltd, a specialty,biopharmaceutical company focused on controlling immune ... phase II clinical study with its,anti-allergy technology, ToleroMune. ... cat-dander allergy, and aims to complete the trial ... on the results of a previous double-blind,placebo-controlled phase ...
Cached Biology Technology:ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 3ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 4ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 5M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer 2Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... a good thing better? A gene known as LIS1 is ... developing brain. When an LIS1 gene is missing, brains fail ... brain, are born severely mentally retarded. But new research by ... recently appeared in Nature Genetics, shows that having ...
... newly described fossil whales--a pregnant female and a male ... and provide new insights into how whales made the ... fossils, discovered in Pakistan in 2000 and 2004, are ... the online journal PLoS. "This stunning ...
... Albert Einstein College of Medicine of Yeshiva University have discovered ... causes disease. The study, published in the ... ( PNAS ), may help scientists develop new therapies or ... fungal infections occur most commonly in those with compromised immune ...
Cached Biology News:Weizmann Institute scientists show extra copies of a gene carry extra risk 2Early whales gave birth on land 2Scientists discover how deadly fungus protects itself 2
... The PowerEase 500 Power Supply ... electrophoresis. It offers extensive programming ... four custom methods for you ... preferences. The simple intuitive PowerEase ...
karyopherin alpha2 (2G7)...
TNF-R2 (L-20)...
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Biology Products: